当前位置: X-MOL 学术Cell Biochem. Funct. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Osteogenic differentiation potential of human bone marrow‐derived mesenchymal stem cells enhanced by bacoside‐A
CELL BIOCHEMISTRY AND FUNCTION ( IF 3.6 ) Pub Date : 2020-11-02 , DOI: 10.1002/cbf.3596
Thiyagarajan Ramesh 1
Affiliation  

Stem cell therapy is growing rapidly to treat numerous diseases including bone‐associated diseases. Mesenchymal stem cells (MSCs) are most commonly preferred to treat bone diseases because it possesses high osteogenic potency. Though, to obtain maximum osteogenic efficiency of MSCs is challenging. Therefore, this study was planned to evaluate the osteogenic efficiency of human bone marrow derived mesenchymal stem cells (hBMSCs) by bacoside‐A. This study was investigated the activity of alkaline phosphatase (ALP) and expressions of the genes specific to osteogenic regulation mainly runt‐related transcription factor 2 (Runx2), osterix (Osx), osteocalcin (OCN) and collagen type Iα1 (Col I α1) in hBMSCs cultured under osteogenic conditions at different concentrations of bacoside‐A for 14 days. The results of this study depicted significant upregulation in the activity of ALP and expressions of osteogenic regulator genes in bacoside‐A treated cells when compared with control cells. Besides, expressions of glycogen synthase kinase‐3β (GSK‐3β) and Wnt/β‐catenin were evaluated; these expressions were also significantly increased in bacoside‐A treated cells when compared with control cells. This result provides a further supporting evidence of bacoside‐A role on osteogenesis in hBMSCs. The present study suggest that bacoside‐A will be applied to ameliorate the process of osteogenesis in hBMSCs to repair damaged bone structure during MSC‐based therapy; this will be an excellent and auspicious treatment for bone‐associated disorders including osteoporosis.

中文翻译:

bacoside-A增强人骨髓间充质干细胞的成骨分化潜能

干细胞疗法正在迅速发展,以治疗包括骨骼相关疾病在内的多种疾病。间充质干细胞(MSCs)最常用于治疗骨疾病,因为它具有很高的成骨能力。但是,要获得MSC的最大成骨效率是一项挑战。因此,本研究计划通过bacoside-A评估人骨髓来源的间充质干细胞(hBMSCs)的成骨效率。这项研究调查了碱性磷酸酶(ALP)的活性以及成骨调节特异性基因的表达,主要是矮子相关转录因子2(Runx2),osterix(Osx),骨钙蛋白(OCN)和Iα1型胶原(Col Iα1)在成骨条件下以不同浓度的bacoside-A培养14天的hBMSC中。这项研究的结果表明,与对照细胞相比,bacoside-A处理的细胞中ALP活性和成骨调节基因的表达显着上调。此外,还评估了糖原合酶激酶-3β(GSK-3β)和Wnt /β-catenin的表达;与对照细胞相比,这些分子在bacoside-A处理的细胞中也显着增加。该结果提供了进一步的支持证据,表明bacoside-A在hBMSCs的成骨中具有作用。本研究表明,bacoside-A将被用于改善hBMSCs的成骨过程,以修复基于MSC的治疗过程中受损的骨骼结构。对于包括骨质疏松症在内的骨相关疾病,这将是一种极好的吉祥疗法。
更新日期:2021-01-07
down
wechat
bug